As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.
Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.
Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, single-pill regimens, announced today that the FDA has approved …
Oppenheimer’s Hartaj Singh notes that Gilead outperformed his 4Q expectations, but continues to play it safe on the giant.
H.C.
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of …
Generics price erosion; the ghost of debt maturation- BTIG’s Tim Chiang sees too many risks to hope for Teva’s recovery anymore.
Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) dropped by as much as 47% in early trading Monday. The reason?
Here’s why $55 million in equity financing could sharpen Viking’s position to explore partnerships and step towards commercialization.
